US FDA lifts clinical hold on <a href="https://laohu8.com/S/NTLA">Intellia</a>’s nerve disease trail Jan 27 (Reuters) - Intellia Therapeutics NTLA.O said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its experimental drug for a rare nerve disease.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments